Literature DB >> 20711074

Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis.

Paul E Marik1, Tajender Vasu, Amyn Hirani, Monvasi Pachinburavan.   

Abstract

BACKGROUND: Recent observational studies suggest that bleeding from stress ulceration is extremely uncommon in intensive care unit patients. Furthermore, the risk of bleeding may not be altered by the use of acid suppressive therapy. Early enteral tube feeding (initiated within 48 hrs of intensive care unit admission) may account for this observation. Stress ulcer prophylaxis may, however, increase the risk of hospital-acquired pneumonia and Clostridia difficile infection.
OBJECTIVE: A systematic review of the literature to determine the benefit and risks of stress ulcer prophylaxis and the moderating effect of enteral nutrition. DATA SOURCES: MEDLINE, Embase, Cochrane Register of Controlled Trials, and citation review of relevant primary and review articles. STUDY SELECTION: Randomized, controlled studies that evaluated the association between stress ulcer prophylaxis and gastrointestinal bleeding. We included only those studies that compared a histamine-2 receptor blocker with a placebo. DATA EXTRACTION: Data were abstracted on study design, study size, study setting, patient population, the histamine-2 receptor blocker and dosage used, the incidence of clinically significant gastrointestinal bleeding, hospital-acquired pneumonia, mortality, and the use of enteral nutrition. DATA SYNTHESIS: Seventeen studies (which enrolled 1836 patients) met the inclusion criteria. Patients received adequate enteral nutrition in three of the studies. Overall, stress ulcer prophylaxis with a histamine-2 receptor blocker reduced the risk of gastrointestinal bleeding (odds ratio 0.47; 95% confidence interval, 0.29-0.76; p < .002; I = 44%); however, the treatment effect was noted only in the subgroup of patients who did not receive enteral nutrition. In those patients who were fed enterally, stress ulcer prophylaxis did not alter the risk of gastrointestinal bleeding (odds ratio 1.26; 95% confidence interval, 0.43-3.7). Overall histamine-2 receptor blockers did not increase the risk of hospital-acquired pneumonia (odds ratio 1.53; 95% confidence interval, 0.89-2.61; p = .12; I = 41%); however, this complication was increased in the subgroup of patients who were fed enterally (odds ratio 2.81; 95% confidence interval, 1.20-6.56; p = .02; I = 0%). Overall, stress ulcer prophylaxis had no effect on hospital mortality (odds ratio 1.03; 95% confidence interval, 0.78-1.37; p = .82). The hospital mortality was, however, higher in those studies (n = 2) in which patients were fed enterally and received a histamine-2 receptor blocker (odds ratio 1.89; 95% confidence interval, 1.04-3.44; p = .04, I = 0%). Sensitivity analysis and meta-regression demonstrated no relationship between the treatment effect (risk of gastrointestinal bleeding) and the classification used to define gastrointestinal bleeding, the Jadad quality score nor the year the study was reported.
CONCLUSIONS: The results of this meta-analysis suggest that, in those patients receiving enteral nutrition, stress ulcer prophylaxis may not be required and, indeed, such therapy may increase the risk of pneumonia and death. However, because no clinical study has prospectively tested the influence of enteral nutrition on the risk of stress ulcer prophylaxis, our findings should be considered exploratory and interpreted with some caution.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20711074     DOI: 10.1097/CCM.0b013e3181f17adf

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  51 in total

1.  Overutilization of proton-pump inhibitors: what the clinician needs to know.

Authors:  Joel J Heidelbaugh; Andrea H Kim; Robert Chang; Paul C Walker
Journal:  Therap Adv Gastroenterol       Date:  2012-07       Impact factor: 4.409

2.  Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults.

Authors:  Stefania Vaglio; Domenico Prisco; Gianni Biancofiore; Daniela Rafanelli; Paola Antonioli; Michele Lisanti; Lorenzo Andreani; Leonardo Basso; Claudio Velati; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2015-12-15       Impact factor: 3.443

3.  Risk factors of ventilator-associated pneumonia in pediatric intensive care unit: a systematic review and meta-analysis.

Authors:  Bo Liu; Song-Qin Li; Su-Ming Zhang; Ping Xu; Xiang Zhang; Yan-Hong Zhang; Wen-Sen Chen; Wei-Hong Zhang
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

4.  Prophylactic proton pump inhibitors in femoral neck fracture patients - A life - and cost-saving intervention.

Authors:  R Singh; R Trickett; Cer Meyer; S Lewthwaite; D Ford
Journal:  Ann R Coll Surg Engl       Date:  2016-04-08       Impact factor: 1.891

Review 5.  Stress ulceration: prevalence, pathology and association with adverse outcomes.

Authors:  Mark P Plummer; Annika Reintam Blaser; Adam M Deane
Journal:  Crit Care       Date:  2014-03-18       Impact factor: 9.097

6.  Primum non nocere and challenging conventional treatment.

Authors:  Adam M Deane; Gordon H Guyatt
Journal:  Intensive Care Med       Date:  2015-04-14       Impact factor: 17.440

Review 7.  What's new with stress ulcer prophylaxis in the ICU?

Authors:  Søren Marker; Mette Krag; Morten Hylander Møller
Journal:  Intensive Care Med       Date:  2017-02-25       Impact factor: 17.440

8.  Guidelines for proton pump inhibitor prescriptions in paediatric intensive care unit.

Authors:  P Joret-Descout; S Dauger; M Bellaiche; O Bourdon; S Prot-Labarthe
Journal:  Int J Clin Pharm       Date:  2017-01-17

Review 9.  Use of Enteral Nutrition for Gastrointestinal Bleeding Prophylaxis in the Critically Ill: Review of Current Literature.

Authors:  Carolyn Newberry; Jessica Schucht
Journal:  Curr Nutr Rep       Date:  2018-09

Review 10.  Stress-related mucosal disease in the critically ill patient.

Authors:  Marc Bardou; Jean-Pierre Quenot; Alan Barkun
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-01-06       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.